First Trust Mid Cap Growth AlphaDEX Fund (FNY) is a publicly traded the market company. As of May 21, 2026, FNY trades at $92.03 with a market cap of $0 and a P/E ratio of 0.00. FNY moved +0.00% today. Year to date, FNY is +0.00%; over the trailing twelve months it is flat. Its 52-week range spans $0.00 to $0.00. Rallies surfaces FNY's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
First Trust Mid Cap Growth AlphaDEX Fund Drops 2.29% on PTC Therapeutics Reversal: First Trust Mid Cap Growth AlphaDEX Fund shares dropped 2.29% after PTC Therapeutics withdrew its New Drug Application for Translarna, signaling weak efficacy data for the DMD therapy. The fund holds a 0.90% weighting in PTC Therapeutics, highlighting potential biotech headwinds for its mid-cap growth strategy.
| Metric | Value |
|---|---|
| Price | $92.03 |
| Market Cap | $0 |
| P/E Ratio | 0.00 |
| EPS | $0.00 |
| Dividend Yield | 0.00% |
| 52-Week High | $0.00 |
| 52-Week Low | $0.00 |
| Volume | 168.48K |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $0 |
| Gross Margin | 0.00% |
FNY analyst coverage data. Average price target: $0.00.